Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The largest research grant ever given for neurodevelopmental conditions has been awarded by the Innovative Medicines Initiative to an international consortium academically led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.

The €115 million grant, titled Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials), will increase our understanding of autism and help develop new therapies to improve health outcomes and quality of life for autistic people.

More than 1 in 100 people are autistic. In addition to the core features of autism, many autistic people struggle with co-occurring conditions such as epilepsy, anxiety and depression, and life expectancy for autistic people can be reduced by up to 30 years.  However, the causes of autism and its associated difficulties remain largely unknown and there are very few effective and autism-appropriate therapies.

The Oxford Translational Molecular Neuroscience Group will undertake the stem cell disease modelling for this consortium to understand gene/environment interactions in autism. The goal is to identify biomarkers and targets that may enable stratified clinical trials and personalised medicine in autism.
- Associate Professor Zameel Cader, Nuffield Department of Clinical Neurosciences

AIMS-2-Trials brings together autistic people and their families, academic institutions, charities and pharmaceutical companies to study autism and provide an infrastructure for developing and testing new therapies. In line with the autism community’s priorities, the consortium will also focus on why some autistic people develop additional health problems that severely impact both quality and length of life.

Professor Declan Murphy, the project academic lead and Director of the Sackler Institute for Translational Neurodevelopment at the IoPPN at King’s says: ‘Many autistic people face extremely poor health outcomes, yet autism research receives far less investment than other conditions which also limit life expectancy and quality of life, such as cancer or dementia. This grant will allow us to bridge the gap between basic biology and the clinic by offering personalised approaches that address problems which really impact autistic people’s lives.’

All autistic people are different which makes identifying and testing new therapies challenging. AIMS-2-Trials will take a precision medicine approach aimed at tailoring therapies to a person’s biological profiles. Achieving this will require developing tests that can predict how a person’s autism may progress throughout development and their likelihood of developing additional mental health problems.

AIMS-2-Trials will create the first European clinical trials network for autism, as well as allowing for international collaborations with charities, government agencies and industry to rapidly determine if therapies are effective. Partnership with autistic people, their families and carers will be a crucial part of developing therapies that achieve the outcomes which matter most to autistic people.

Dr James Cusack, Director of Science at Autistica, a UK charity supporting AIMS-2-Trials, says: ‘Autistic people deserve an equal right to a long, healthy happy life.  To deliver on that vision, we're working together to understand why autistic people are different from each other. We're excited to be joining this consortium to ensure that the views of autistic people and their families are considered throughout the project.’

Professor Louis Reichardt, Director of the Simons Foundation Autism Research Initiative (SFARI) says: ‘The development of new and effective therapies for autism is a daunting task that requires the talents, efforts, and resources of public, private, and non-profit sectors. The scientists at SFARI will be working with AIMS-2-Trials investigators on many of the project's initiatives, and we look forward to the project's success.’

Through the Innovative Medicines Initiative, European Union funding matches in-kind contributions from autism charities and the pharmaceutical industry, with nearly €60 million provided by charities, and €2.5 million from the European Federation of Pharmaceutical Industries and Associations (EFPIA).

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, Simons Foundation, Autism Speaks, and Autistica. 

Similar stories

Celebrating NDCN at Thomas Willis Day 2026

Our annual event where we join together to celebrate our people and the work of our NDCN over the last year. Nearly 250 staff and students came together for this year's event on Tuesday 16 June at the Mathematical Institute.

Kate Watkins and Bernhard Staresina awarded major European Research Council Advanced Grants

Kate and Bernhard were two of fourteen researchers at the University of Oxford to be awarded Advanced Grants from the European Research Council (ERC), each worth up to €2.5 million over a period of five years.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Dr Ruxandra Dafinca awarded an Alzheimer’s Society Dementia Research Leader Fellowship

Ruxandra Dafinca is one of 17 early career researchers awarded a fellowship in the 2025/2026 call for her project focused on frontotemporal dementia.

New study shows the brain uses brief, slow rhythms to organise how memories are formed, stored, and later recalled

A new study from the University of Oxford and CNRS has shown that the brain uses rhythms for brain cell impulses to coordinate activity across memory-related regions in the brain during learning and help reactivate those experiences afterwards, strengthening what we remember.

Clinical Trial of Ketogenic Therapy for Early Psychosis funded by Baszucki Group

The University Oxford has received £1.17m of funding from Baszucki Group to assess the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P).

The 50th Anniversary of the Oxford Self-harm Monitoring System

Influential and impactful Oxford Self-harm Monitoring System had been in place, and continuously funded, for 50 years.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease

Oxford researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.

Similar stories

Celebrating NDCN at Thomas Willis Day 2026

Our annual event where we join together to celebrate our people and the work of our NDCN over the last year. Nearly 250 staff and students came together for this year's event on Tuesday 16 June at the Mathematical Institute.

Kate Watkins and Bernhard Staresina awarded major European Research Council Advanced Grants

Kate and Bernhard were two of fourteen researchers at the University of Oxford to be awarded Advanced Grants from the European Research Council (ERC), each worth up to €2.5 million over a period of five years.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Dr Ruxandra Dafinca awarded an Alzheimer’s Society Dementia Research Leader Fellowship

Ruxandra Dafinca is one of 17 early career researchers awarded a fellowship in the 2025/2026 call for her project focused on frontotemporal dementia.

New study shows the brain uses brief, slow rhythms to organise how memories are formed, stored, and later recalled

A new study from the University of Oxford and CNRS has shown that the brain uses rhythms for brain cell impulses to coordinate activity across memory-related regions in the brain during learning and help reactivate those experiences afterwards, strengthening what we remember.